ArticleLancet (London, England)2019
Pembrolizumab for all PD-L1-positive NSCLC.
Egbert F Smit et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
12 papers cite it
this papercites it
ArticleLancet (London, England)2019
Egbert F Smit et al.PubMed ↗Publisher ↗
No numbers read from the abstract.